Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 5
1946 12
1947 12
1948 19
1949 13
1950 20
1951 33
1952 34
1953 35
1954 33
1955 27
1956 28
1957 30
1958 37
1959 28
1960 28
1961 33
1962 33
1963 41
1964 57
1965 28
1966 42
1967 58
1968 90
1969 108
1970 113
1971 115
1972 119
1973 115
1974 102
1975 132
1976 121
1977 117
1978 124
1979 127
1980 134
1981 132
1982 162
1983 154
1984 169
1985 169
1986 221
1987 184
1988 191
1989 303
1990 257
1991 285
1992 320
1993 300
1994 348
1995 383
1996 488
1997 544
1998 600
1999 687
2000 785
2001 798
2002 835
2003 1064
2004 992
2005 1172
2006 1163
2007 1303
2008 1545
2009 1669
2010 1856
2011 2032
2012 2332
2013 2454
2014 2765
2015 2993
2016 3105
2017 3122
2018 3264
2019 3242
2020 4305
2021 4637
2022 4297
2023 3815
2024 1361

Text availability

Article attribute

Article type

Publication date

Search Results

58,384 results

Results by year

Filters applied: . Clear all
Page 1
Oral Anticoagulation.
Altiok E, Marx N. Altiok E, et al. Dtsch Arztebl Int. 2018 Nov 16;115(46):776-783. doi: 10.3238/arztebl.2018.0776. Dtsch Arztebl Int. 2018. PMID: 30602410 Free PMC article. Review.
BACKGROUND: Much new evidence on oral anticoagulation has come to light in recent years. Non-vitamin-K-dependent oral anti- coagulants (NOAC) have been developed and have been introduced into clinical practice. In this review, we present the current state of the evi …
BACKGROUND: Much new evidence on oral anticoagulation has come to light in recent years. Non-vitamin-K-dependent oral anti- co …
Interaction Between Dietary Vitamin K Intake and Anticoagulation by Vitamin K Antagonists: Is It Really True?: A Systematic Review.
Violi F, Lip GY, Pignatelli P, Pastori D. Violi F, et al. Medicine (Baltimore). 2016 Mar;95(10):e2895. doi: 10.1097/MD.0000000000002895. Medicine (Baltimore). 2016. PMID: 26962786 Free PMC article.
Educational advice is often given to patients starting treatment with vitamin K Antagonists (VKAs). A great emphasis is made on nutritional information. ...We found conflicting evidence on the effect of dietary intake of vitamin K on coagulation …
Educational advice is often given to patients starting treatment with vitamin K Antagonists (VKAs). A great emphasis is …
Use of the SAMe-TT(2)R(2) score to predict anticoagulation control in atrial fibrillation and venous thromboembolism patients receiving vitamin K antagonists: A review.
Zulkifly H, Lip GYH, Lane DA. Zulkifly H, et al. Heart Rhythm. 2018 Apr;15(4):615-623. doi: 10.1016/j.hrthm.2017.11.026. Epub 2017 Nov 24. Heart Rhythm. 2018. PMID: 29180122 Review.
Identifying patients who are likely to achieve and maintain a therapeutic international normalized ratio when prescribed a vitamin K antagonist for stroke prevention in atrial fibrillation (AF) and venous thromboembolism (VTE) is challenging. .. …
Identifying patients who are likely to achieve and maintain a therapeutic international normalized ratio when prescribed a vitamin …
Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism.
Andras A, Sala Tenna A, Crawford F. Andras A, et al. Cochrane Database Syst Rev. 2012 Oct 17;10:CD002001. doi: 10.1002/14651858.CD002001.pub2. Cochrane Database Syst Rev. 2012. PMID: 23076894 Updated. Review.
BACKGROUND: People with venous thromboembolism (VTE) are generally treated for five days with intravenous unfractionated heparin or subcutaneous low-molecular-weight heparin (LMWH) followed by three months of vitamin K antagonist treatment. ...H …
BACKGROUND: People with venous thromboembolism (VTE) are generally treated for five days with intravenous unfractionated hepar …
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism.
Middeldorp S, Prins MH, Hutten BA. Middeldorp S, et al. Cochrane Database Syst Rev. 2014 Aug 5;2014(8):CD001367. doi: 10.1002/14651858.CD001367.pub3. Cochrane Database Syst Rev. 2014. PMID: 25092359 Free PMC article. Review.
OBJECTIVES: To evaluate the efficacy and safety of different durations of treatment with vitamin K antagonists in patients with symptomatic venous thromboembolism. ...SELECTION CRITERIA: Randomized controlled clinical trials comparing different …
OBJECTIVES: To evaluate the efficacy and safety of different durations of treatment with vitamin K antagonists in patie …
Primary and secondary prophylaxis of venous thromboembolism with low-molecular-weight heparins: prolonged thromboprophylaxis, an alternative to vitamin K antagonists.
Kher A, Samama MM. Kher A, et al. J Thromb Haemost. 2005 Mar;3(3):473-81. doi: 10.1111/j.1538-7836.2005.01180.x. J Thromb Haemost. 2005. PMID: 15748236 Free article. Review.
Low-molecular-weight heparins (LMWHs) are used widely in the treatment and prevention of venous thromboembolism (VTE). The LMWHs dalteparin and enoxaparin reduce the rate of VTE by at least 50% if administered for 4-5 weeks following major orthopedic surgery, compar …
Low-molecular-weight heparins (LMWHs) are used widely in the treatment and prevention of venous thromboembolism (VTE). The LMW …
Non-vitamin K antagonist oral anticoagulants for the prevention of recurrent venous thromboembolism.
Bauersachs R. Bauersachs R. Thromb Res. 2016 Aug;144:12-20. doi: 10.1016/j.thromres.2016.05.022. Epub 2016 May 20. Thromb Res. 2016. PMID: 27263046 Review.
Venous thromboembolism (VTE) is associated with a risk of recurrence that depends on factors specific to index event and patient. ...Determining a strategy for the long-term prevention of recurrent VTE poses challenges that stem from a lack of agreement on recommend …
Venous thromboembolism (VTE) is associated with a risk of recurrence that depends on factors specific to index event and patie …
Novel or non-vitamin K antagonist oral anticoagulants and the treatment of cancer-associated thrombosis.
Wu C, Lee AY. Wu C, et al. Semin Thromb Hemost. 2015 Mar;41(2):237-43. doi: 10.1055/s-0035-1544160. Epub 2015 Feb 15. Semin Thromb Hemost. 2015. PMID: 25682086 Review.
Despite advances in therapy using low-molecular-weight heparins, both venous thromboembolic recurrence and clinically relevant bleeding while on therapeutic anticoagulation occur at high rates. Multiple novel (or non-vitamin K antagonist) oral a …
Despite advances in therapy using low-molecular-weight heparins, both venous thromboembolic recurrence and clinically relevant …
Extended non-vitamin K antagonist oral anticoagulation therapy for prevention of recurrent venous thromboembolism.
Piovella F, Iosub DI. Piovella F, et al. Thromb Res. 2017 Apr;152:87-92. doi: 10.1016/j.thromres.2016.12.001. Epub 2016 Dec 7. Thromb Res. 2017. PMID: 28017344 Review.
Evidence from the use of traditional therapy (low-molecular-weight heparin/vitamin K antagonists) for venous thromboembolism (VTE) treatment and prevention suggests that extending treatment beyond the acute phase reduces recurrence. More recentl …
Evidence from the use of traditional therapy (low-molecular-weight heparin/vitamin K antagonists) for venous …
Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease.
Voukalis C, Lip GY, Shantsila E. Voukalis C, et al. Expert Opin Pharmacother. 2016 Oct;17(15):2033-47. doi: 10.1080/14656566.2016.1232393. Expert Opin Pharmacother. 2016. PMID: 27667112 Review.
INTRODUCTION: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the western world. The approval of non-vitamin K oral anticoagulants (NOACs) as antithrombotic alternatives to vitamin K antagonists (VKAs) h …
INTRODUCTION: Venous thromboembolism (VTE) is a major cause of morbidity and mortality in the western world. The approval of n …
58,384 results
You have reached the last available page of results. Please see the User Guide for more information.